LeonaBio (LONA) Cash & Equivalents (2019 - 2026)

LeonaBio (LONA) has 8 years of Cash & Equivalents data on file, last reported at $32.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $32.8 million, up 24.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.8 million (up 24.26% YoY), and the FY2025 annual result was $69.3 million, up 43.02% from the prior year.
• Cash & Equivalents retreated to $32.8 million in Q1 2026 per LONA's latest filing, from $69.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $117.8 million in Q1 2022 and troughed at $19.9 million in Q2 2025.
• A 5-year average of $73.8 million and a median of $77.8 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 43.02% in 2025 and fell as far as 73.06% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $96.0 million in 2022, then retreated by 5.61% to $90.6 million in 2023, then plunged by 46.53% to $48.4 million in 2024, then soared by 43.02% to $69.3 million in 2025, then slumped by 52.61% to $32.8 million in 2026.
• Business Quant data shows LONA's Cash & Equivalents at $32.8 million in Q1 2026, $69.3 million in Q4 2025, and $20.9 million in Q3 2025.